QT Sense closes €4M round to support real-time cell analysis

February 4, 2026 at 08:15 AM UTC
Tech.eu
Original: EN
QT Sense closes €4M round to support real-time cell analysis

Dutch startup QT Sense has secured €4 million in funding to advance its Quantum Nuova platform, a quantum-based system designed for real-time, single-cell resolution analysis of cellular stress. This funding, comprising a €3 million seed round led by Cottonwood Technology Fund and contributions from QDNL Participations and an angel investor, alongside significant grant funding, underscores the growing interest in cutting-edge life science technologies. The investment aims to accelerate the development and deployment of Quantum Nuova, positioning it as a significant tool in biological research and potential therapeutic development. Quantum Nuova distinguishes itself by enabling the measurement of biochemical activity in living cells and tissues in real time, a departure from traditional methods that often analyze static or non-living samples. The platform utilizes fluorescent nanodiamond quantum sensors to detect critical cellular signals such as oxidative stress and metabolic changes, which are crucial indicators of disease processes but have historically been challenging to observe directly at the cellular level. This granular insight into cellular behavior in a live state offers researchers unprecedented opportunities to study drug responses, cellular adaptation to stress, and cell differentiation, providing complementary data to genomics and proteomics. The immediate impact of this funding will be the transition of Quantum Nuova from a functional prototype to a robust, deployable discovery platform. Further development will focus on enhancing hardware capabilities, increasing throughput, and integrating advanced analytics to support real-world applications. With a portion of the funding dedicated to oncology research through an ONCO-Q grant, the platform will be applied to study colorectal cancer, aiming to map oxidative stress and metabolic vulnerabilities in tumour models. Early access to the technology will be provided to strategic partners for mechanism-of-action studies and functional heterogeneity analysis, paving the way for future diagnostic and therapeutic advancements.

Curated and translated by Europe Digital for our multilingual European audience.

Source Information

Publication: Tech.eu
Published: February 4, 2026 at 08:15 AM UTC
All rights remain with the original publisher.